This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2 Mar 2011

Takeda Hypertension Drug Edarbi Approved in US

The FDA approved Takeda's Edarbi (azilsartan) for the treatment of hypertension in adults.

Takeda Pharmaceutical has received approval from the US FDA for Edarbi tablets (azilsartan medoxomil) to treat hypertension in adults. Edarbi tablets will be available in 40mg and 80mg doses, with the recommended dosage being 80mg once daily.


Results from clinical studies revealed that Edarbi was more effective at lowering 24-hour blood pressure compared to two other FDA-approved hypertension drugs, Diovan (valsartan) and Benicar (olmesartan).


Adverse events reported by patients taking Edarbi in the trial were similar to those reported by placebo receiving patients.


The 40mg dose will be indicated for patients who are treated with high-dose diuretics

Related News